MESOM
MCID: MST023
MIFTS: 61

Mesothelioma, Malignant (MESOM)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Mesothelioma, Malignant

MalaCards integrated aliases for Mesothelioma, Malignant:

Name: Mesothelioma, Malignant 57 53 75 29 44 40
Malignant Mesothelioma 12 53 55 15 73
Advanced Malignant Mesothelioma 12 73
Mesothelioma, Somatic 57 13
Pleural Mesothelioma 59 73
Mesom 57 75
Asbestos-Related Malignant Mesothelioma 12
Diffuse Malignant Mesothelioma 12
Malignant Tumor of Mesothelium 12
Malignant Pleural Mesothelioma 73
Mesothelioma Diffuse Malignant 55
Mesothelioma 73

Characteristics:

Orphanet epidemiological data:

59
pleural mesothelioma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

OMIM:

57
Inheritance:
somatic mutation

Miscellaneous:
etiologically linked to asbestos
may be seen in conjunction with other cancer syndromes (e.g., tdps )


HPO:

32
mesothelioma, malignant:
Inheritance somatic mutation


Classifications:

Orphanet: 59  
Rare respiratory diseases


External Ids:

OMIM 57 156240
Disease Ontology 12 DOID:1790
SNOMED-CT 68 62064005
Orphanet 59 ORPHA50251
UMLS via Orphanet 74 C0025500 C0812413 C1377913
MESH via Orphanet 45 D008654
ICD10 via Orphanet 34 C45.0
MedGen 42 C0345967

Summaries for Mesothelioma, Malignant

NIH Rare Diseases : 53 Malignant mesothelioma is a form of cancer that develops in the thin layer of tissue that surrounds the lungs, chest wall, or abdomen. Signs and symptoms of the condition can vary and often depend on which area of the body is affected. Common features include abdominal bloating, abdominal pain, chest pain, coughing, fatigue, shortness of breath, and/or weight loss. Malignant mesothelioma is thought to be caused by long-term exposure to asbestos (a fire-resistant material that was once commonly found in insulation; ceiling and roof vinyls; cement; and automotive brake materials). Most people appear to be diagnosed with the condition approximately 30 years after being in contact with the asbestos. Unfortunately, there is generally no cure for malignant mesothelioma unless it is diagnosed at an early stage and can be surgically removed. If surgery is not an option, chemotherapy and/or radiation therapy may still be recommended to help alleviate some of the associated symptoms.

MalaCards based summary : Mesothelioma, Malignant, also known as malignant mesothelioma, is related to malignant epithelial mesothelioma and peritoneal mesothelioma, and has symptoms including fatigue, dyspnea and chest pain. An important gene associated with Mesothelioma, Malignant is BCL10 (BCL10, Immune Signaling Adaptor), and among its related pathways/superpathways are Cytoskeletal Signaling and MicroRNAs in cancer. The drugs Alimta and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include lung, testis and heart, and related phenotypes are dysphagia and hepatomegaly

Disease Ontology : 12 A cell type cancer that has material basis in mesothelial tissue that develops from the thin layer of tissue that covers many of the internal organs.

OMIM : 57 Malignant mesothelioma is an aggressive neoplasm of the serosal lining of the chest etiologically linked to asbestos. It is diagnosed in approximately 2,000 to 3,000 individuals annually in the United States, most of whom die within 2 years of diagnosis (summary by Bott et al., 2011). See also 614327 for a tumor predisposition syndrome that may contribute to the development of malignant mesothelioma upon asbestos exposure and is caused by germline mutation in the BAP1 gene (603089) on chromosome 3p21. (156240)

UniProtKB/Swiss-Prot : 75 Mesothelioma, malignant: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos.

Wikipedia : 76 Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the... more...

Related Diseases for Mesothelioma, Malignant

Diseases in the Benign Mesothelioma family:

Mesothelioma, Malignant Benign Intermediate Mesothelioma

Diseases related to Mesothelioma, Malignant via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 250)
# Related Disease Score Top Affiliating Genes
1 malignant epithelial mesothelioma 33.0 THBD WT1
2 peritoneal mesothelioma 32.4 WT1 THBD NF2 MUC1 CDKN2A BAP1
3 malignant pleural mesothelioma 32.4 WT1 THBD SPP1 NKX2-1 MUC1 MSLN
4 pericardial mesothelioma 32.1 VIM THBD MUC1 MSLN KRT7 CALB2
5 malignant biphasic mesothelioma 31.9 WT1 THBD MSLN KRT7 CALB2
6 sarcomatoid mesothelioma 31.8 WT1 VIM THBD NKX2-1 CDKN2A
7 benign mesothelioma 31.1 KRT7 WT1
8 malignant peritoneal mesothelioma 31.1 VIM NF2 MUC1 CDKN2A
9 pleural disease 30.4 BAP1 CALB2 MSLN SPP1
10 sarcoma, synovial 30.3 VIM MUC1 KRT7 CALB2
11 wilms tumor 1 30.2 CALB2 KRT7 NKX2-1 WT1
12 papillary adenocarcinoma 30.1 VIM NKX2-1 MUC1 KRT7
13 mucinous cystadenocarcinoma 30.1 KRT7 MUC1 VIM
14 epithelioid sarcoma 30.1 KRT7 MUC1 VIM
15 carcinosarcoma 30.0 KRT7 MUC1 VIM
16 lung cancer susceptibility 3 30.0 NKX2-1 MUC1 MSLN KRT7 CDKN2A CDH2
17 lymphohistiocytoid mesothelioma 30.0 THBD CDKN2A CALB2
18 adenoid squamous cell carcinoma 30.0 KRT7 VIM
19 small cell carcinoma 30.0 CDKN2A KRT7 NKX2-1
20 spindle cell sarcoma 29.9 VIM NF2 MUC1 KRT7
21 pleural cancer 29.8 WT1 SPP1 NF2 MSLN CDKN2A CALB2
22 renal cell carcinoma, nonpapillary 29.7 KRT7 MIR584 MUC1 NKX2-1 VIM WT1
23 adenomatoid tumor 29.7 WT1 VIM THBD NKX2-1 KRT7 CALB2
24 small cell cancer of the lung 29.5 CDKN2A KRT7 NKX2-1
25 benign pleural mesothelioma 12.5
26 ovarian malignant mesothelioma 12.2
27 tumor predisposition syndrome 11.3
28 bap1 tumor predisposition syndrome 11.2
29 adenocarcinoma 10.5
30 lung cancer 10.4
31 fallopian tube carcinosarcoma 10.3 CALB2 WT1
32 fallopian tube squamous cell carcinoma 10.3 CDKN2A WT1
33 transitional meningioma 10.3 MUC1 NF2
34 optic nerve sheath meningioma 10.3 CDKN2A NF2
35 renal adenoma 10.3 KRT7 WT1
36 ovarian serous cystadenofibroma 10.3 CALB2 MUC1
37 melanomatosis 10.3 CDKN2A WT1
38 epithelial predominant wilms' tumor 10.3 KRT7 WT1
39 ovarian small cell carcinoma 10.3 MUC1 WT1
40 fallopian tube endometrioid adenocarcinoma 10.3 CALB2 CDKN2A
41 rhabdoid meningioma 10.3 VIM NF2 BAP1
42 peritoneum cancer 10.3 BAP1 KRT7 WT1
43 ovarian germ cell teratoma 10.3 KRT7 NKX2-1
44 lung acinar adenocarcinoma 10.3 KRT7 NKX2-1
45 inverted transitional papilloma 10.3 CDKN2A KRT7
46 chordoid glioma 10.3 NKX2-1 NF2 MUC1
47 small cell carcinoma of the bladder 10.3 KRT7 NKX2-1
48 cornea cancer 10.3 CDKN2A NF2
49 gynandroblastoma 10.3 CALB2 VIM
50 ovarian germ cell cancer 10.3 KRT7 NKX2-1

Graphical network of the top 20 diseases related to Mesothelioma, Malignant:



Diseases related to Mesothelioma, Malignant

Symptoms & Phenotypes for Mesothelioma, Malignant

Symptoms via clinical synopsis from OMIM:

57
Respiratory Lung:
mesothelioma, malignant

Neoplasia:
mesothelioma


Clinical features from OMIM:

156240

Human phenotypes related to Mesothelioma, Malignant:

59 32 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002015
2 hepatomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0002240
3 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
4 respiratory distress 59 32 frequent (33%) Frequent (79-30%) HP:0002098
5 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
6 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
7 abnormality of cardiovascular system physiology 59 32 occasional (7.5%) Occasional (29-5%) HP:0011025
8 lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002716
9 pleural effusion 59 32 hallmark (90%) Very frequent (99-80%) HP:0002202
10 fourth cranial nerve palsy 59 32 occasional (7.5%) Occasional (29-5%) HP:0007011
11 obstruction of the superior vena cava 59 32 occasional (7.5%) Occasional (29-5%) HP:0031041
12 dyspnea 59 Frequent (79-30%)
13 abnormality of the thorax 59 Frequent (79-30%)
14 abnormality of the pleura 59 Frequent (79-30%)
15 functional respiratory abnormality 59 Occasional (29-5%)
16 abnormality of lung morphology 59 Occasional (29-5%)
17 constitutional symptom 59 Frequent (79-30%)
18 malignant mesothelioma 32 HP:0100001

UMLS symptoms related to Mesothelioma, Malignant:


fatigue, dyspnea, chest pain, chills, malaise

MGI Mouse Phenotypes related to Mesothelioma, Malignant:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.76 BAP1 BCL10 CDH2 CDKN2A NF2 THBD
2 neoplasm MP:0002006 9.43 BAP1 CDKN2A NF2 NKX2-1 SPP1 WT1
3 respiratory system MP:0005388 9.23 BAP1 CDKN2A NF2 NKX2-1 SPP1 THBD

Drugs & Therapeutics for Mesothelioma, Malignant

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004

Drugs for Mesothelioma, Malignant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 298)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
2
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150399-23-8, 137281-23-3 446556 60843
3
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
4 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
11
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
12
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
13
Hydroxocobalamin Approved Phase 2, Phase 3,Phase 3 13422-51-0 11953898 44475014
14
Methylcobalamin Approved, Experimental, Investigational Phase 2, Phase 3,Phase 3 13422-55-4
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
17
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
18
Vorinostat Approved, Investigational Phase 3,Phase 1,Phase 2 149647-78-9 5311
19
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
20
Raltitrexed Approved, Investigational Phase 3,Phase 2,Phase 1 112887-68-0 104758
21
Nintedanib Approved Phase 3,Phase 2,Phase 1 656247-17-5 56843413
22
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
23
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
25
Nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
26
Celecoxib Approved, Investigational Phase 3,Phase 1,Phase 2 169590-42-5 2662
27
Pembrolizumab Approved Phase 2, Phase 3,Phase 3,Phase 1 1374853-91-4
28
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3,Phase 3 68-19-9 44176380
29
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
30 Ranpirnase Investigational Phase 3 196488-72-9
31
Cobalamin Experimental Phase 2, Phase 3,Phase 3 13408-78-1 6438156
32 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
35 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
36 Mitomycins Phase 3,Phase 2
37 Antimitotic Agents Phase 3,Phase 2,Phase 1
38 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
39 Alkylating Agents Phase 3,Phase 2,Phase 1
40 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
41 Antimetabolites Phase 3,Phase 2,Phase 1
42 Analgesics Phase 3,Phase 1,Phase 2
43 Antiemetics Phase 3,Phase 2,Phase 1
44 Vitamins Phase 2, Phase 3,Phase 3,Phase 1
45 Vitamin B 12 Phase 2, Phase 3,Phase 3
46 Vitamin B12 Phase 2, Phase 3,Phase 3
47 Micronutrients Phase 3,Phase 2,Phase 1
48 Autonomic Agents Phase 3,Phase 2,Phase 1
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
50 Gastrointestinal Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 403)
# Name Status NCT ID Phase Drugs
1 Dose Individualization of Pemetrexed - IMPROVE-III Not yet recruiting NCT03655834 Phase 4 Pemetrexed
2 Dose Individualization of Pemetrexed - IMPROVE-II Not yet recruiting NCT03655821 Phase 4 Pemetrexed
3 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
4 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1) Completed NCT00128102 Phase 3 vorinostat;Placebo
5 Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
6 Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
7 Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura Completed NCT00004920 Phase 3 cisplatin;raltitrexed
8 Nintedanib (BIBF 1120) in Mesothelioma Completed NCT01907100 Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
9 A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
10 Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma Completed NCT00006231 Phase 3
11 Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma Completed NCT00821860 Phase 3
12 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
13 Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
14 Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma Recruiting NCT03063450 Phase 3 Nivolumab
17 Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Recruiting NCT02784171 Phase 2, Phase 3 Cisplatin;Pemetrexed;Pembrolizumab
18 Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
19 DENdritic Cell Immunotherapy for Mesothelioma Recruiting NCT03610360 Phase 2, Phase 3 MesoPher
20 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Active, not recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
21 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Active, not recruiting NCT02899299 Phase 3 Pemetrexed;Cisplatin;Carboplatin
22 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
23 Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma Not yet recruiting NCT03710876 Phase 3 Celecoxib Oral Product;Gemcitabine
24 BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma Not yet recruiting NCT03762018 Phase 3 Carboplatin;Pemetrexed;Bevacizumab;Atezolizumab
25 PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Terminated NCT01604005 Phase 3
26 Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication Withdrawn NCT02511600 Phase 3
27 A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma Unknown status NCT01649024 Phase 2 Tremelimumab
28 An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma Unknown status NCT00685204 Phase 2 Milataxel
29 The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma Unknown status NCT01655888 Phase 2 Tremelimumab
30 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
31 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
32 A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
33 Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma Unknown status NCT00030459 Phase 2 cisplatin;mitomycin C;vinblastine sulfate;vinorelbine tartrate
34 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
35 Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
36 Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
37 Combination Gene Transfer and Chemotherapy Unknown status NCT01119664 Phase 1, Phase 2 SCH 721015
38 Sorafenib in Previously Treated Malignant Mesothelioma Unknown status NCT00794859 Phase 2 Sorafenib
39 Trimodal Lung-Sparing Treatment of Pleural Mesothelioma Unknown status NCT00859495 Phase 2 Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
40 A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine
41 Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma Unknown status NCT01281800 Phase 2
42 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Unknown status NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
43 A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
44 High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma Unknown status NCT00002465 Phase 1, Phase 2 megestrol acetate
45 Four Versus Six Cycles of Pemetrexed/Platinum for MPM Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
46 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
47 MPM PDT Phase II Trial Unknown status NCT02153229 Phase 2 Photofrin 2.0 mg/kg
48 Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Unknown status NCT02349958 Phase 2
49 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
50 Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients Unknown status NCT01134250 Phase 1, Phase 2 F16IL2 in combination with paclitaxel

Search NIH Clinical Center for Mesothelioma, Malignant

Cochrane evidence based reviews: mesothelioma, malignant

Genetic Tests for Mesothelioma, Malignant

Genetic tests related to Mesothelioma, Malignant:

# Genetic test Affiliating Genes
1 Mesothelioma, Malignant 29 BCL10 WT1

Anatomical Context for Mesothelioma, Malignant

MalaCards organs/tissues related to Mesothelioma, Malignant:

41
Lung, Testis, Heart, T Cells, Skin, Liver, Testes

Publications for Mesothelioma, Malignant

Articles related to Mesothelioma, Malignant:

(show top 50) (show all 398)
# Title Authors Year
1
18F-FDG PET/CT Revealing Constrictive Pericarditis as the Only Manifestation of Malignant Mesothelioma. ( 30371590 )
2018
2
Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma. ( 30111297 )
2018
3
A Case of Amelanotic Malignant Melanoma with Dense Pleural Thickening Mimicking Malignant Mesothelioma. ( 30449771 )
2018
4
Malignant mesothelioma presenting as recurrent hydro-pneumothorax: An atypical case presentation and literature review. ( 29719805 )
2018
5
Pleural malignant mesothelioma versus pleuropulmonary synovial sarcoma: a clinicopathological study of 22 cases with molecular analysis and survival data. ( 30170702 )
2018
6
Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines. ( 30040460 )
2018
7
Genomics and Epigenetics of Malignant Mesothelioma. ( 30060501 )
2018
8
Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways. ( 30061637 )
2018
9
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. ( 30113886 )
2018
10
Personalized treatment of malignant mesothelioma-dream or reality? ( 30123547 )
2018
11
Letter to the editor re: Dragani et al. (2018), "Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure". ( 30137211 )
2018
12
Molecular and Ultrastructural Features of Diffuse Intrapulmonary Malignant Mesothelioma. ( 30138217 )
2018
13
Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22. ( 30197002 )
2018
14
Letter concerning: 'Response to: 'The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure' by Marinaccio et al'. ( 30209209 )
2018
15
Response to: 'The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure' by Marinaccio et al. ( 30209210 )
2018
16
An Occupational Legacy: Malignant Mesothelioma Incidence and Mortality in Wisconsin. ( 30256306 )
2018
17
Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. ( 30259640 )
2018
18
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. ( 30266660 )
2018
19
Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes. ( 30268487 )
2018
20
Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma. ( 30272283 )
2018
21
Primary Sarcomatoid Malignant Mesothelioma of the Pancreas. ( 30298421 )
2018
22
Analysis of YAP1 and TAZ expression by immunohistochemical staining in malignant mesothelioma and reactive mesothelial cells. ( 30344759 )
2018
23
Ferruginous bodies resolved by synchrotron XRF in a dog with peritoneal malignant mesothelioma. ( 30357666 )
2018
24
Malignant mesothelioma of tunica vaginalis testis: Report of a very rare case with review of the literature. ( 30362690 )
2018
25
Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma. ( 30370397 )
2018
26
Peritoneal Deciduoid Malignant Mesothelioma on 67Ga SPECT/CT. ( 30394926 )
2018
27
Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. ( 30410729 )
2018
28
Role of p16 deletion and BAP1 loss in the diagnosis of malignant mesothelioma. ( 30416802 )
2018
29
Pleural mesothelioma in Poland: Spatial analysis of malignant mesothelioma prevalence in the period 1999-2013. ( 30451473 )
2018
30
Effect of the BH3 Mimetic Polyphenol (-)-Gossypol (AT-101) on the in vitro and in vivo Growth of Malignant Mesothelioma. ( 30459622 )
2018
31
3D Culture Models of Malignant Mesothelioma Reveal a Powerful Interplay Between Photodynamic Therapy and Kinase Suppression Offering Hope to Reduce Tumor Recurrence. ( 30485439 )
2018
32
Molecular Characterization of Malignant Mesothelioma: Time for New Targets? ( 30510013 )
2018
33
Case report of inguinal metastasis of epididymal malignant mesothelioma. ( 30511195 )
2018
34
The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology. ( 30520251 )
2018
35
Genomic changes of chromosomes 8p23.1 and 1q21: Novel mutations in malignant mesothelioma. ( 30527173 )
2018
36
Calretinin Functions in Malignant Mesothelioma Cells Cannot Be Replaced by the Closely Related Ca2+-Binding Proteins Calbindin-D28k and Parvalbumin. ( 30545133 )
2018
37
Calretinin promotes invasiveness and EMT in malignant mesothelioma cells involving the activation of the FAK signaling pathway. ( 30555628 )
2018
38
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. ( 28686500 )
2018
39
Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma. ( 28884745 )
2018
40
Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions. ( 28994508 )
2018
41
Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma. ( 29076876 )
2018
42
Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples. ( 29227332 )
2018
43
Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study. ( 29241740 )
2018
44
Evaluation of RET Gene Rearrangement by Fluorescence In Situ Hybridization in Malignant Mesothelioma. ( 29258668 )
2018
45
Micro-RNA149 confers taxane resistance to malignant mesothelioma cells via regulation of P-glycoprotein expression. ( 29261027 )
2018
46
The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure. ( 29269563 )
2018
47
Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo. ( 29298350 )
2018
48
Correction: Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer. ( 29298805 )
2018
49
SMARCB1/INI1/BAF47- deficient pleural malignant mesothelioma with rhabdoid features. ( 29316066 )
2018
50
Genome Evolution Analysis of Recurrent Testicular Malignant Mesothelioma by Whole-Genome Sequencing. ( 29334678 )
2018

Variations for Mesothelioma, Malignant

ClinVar genetic disease variations for Mesothelioma, Malignant:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 WT1 NM_024426.4(WT1): c.1021A> G (p.Ser341Gly) single nucleotide variant Pathogenic rs121907908 GRCh37 Chromosome 11, 32421571: 32421571
2 WT1 NM_024426.4(WT1): c.1021A> G (p.Ser341Gly) single nucleotide variant Pathogenic rs121907908 GRCh38 Chromosome 11, 32400025: 32400025
3 BCL10 NM_003921.4(BCL10): c.499_500insT (p.Ser167Phefs) insertion Pathogenic rs387906350 GRCh37 Chromosome 1, 85733513: 85733513
4 BCL10 NM_003921.4(BCL10): c.499_500insT (p.Ser167Phefs) insertion Pathogenic rs387906350 GRCh38 Chromosome 1, 85267830: 85267830
5 BCL10 NM_003921.4(BCL10): c.136delA (p.Ile46Tyrfs) deletion Pathogenic rs587776639 GRCh37 Chromosome 1, 85736511: 85736511
6 BCL10 NM_003921.4(BCL10): c.136delA (p.Ile46Tyrfs) deletion Pathogenic rs587776639 GRCh38 Chromosome 1, 85270828: 85270828

Copy number variations for Mesothelioma, Malignant from CNVD:

7 (show all 35)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13405 1 1 2300000 Loss Malignant mesothelioma
2 21838 1 16200000 28000000 Loss Malignant mesothelioma
3 33950 1 50700000 61300000 Amplification Malignant mesothelioma
4 35952 1 69700000 116100000 Loss Malignant mesothelioma
5 35954 1 69700000 116100000 Loss CLCA1 Malignant mesothelioma
6 35956 1 69700000 116100000 Loss CLCA2 Malignant mesothelioma
7 35958 1 69700000 116100000 Loss CLCA3 Malignant mesothelioma
8 35960 1 69700000 116100000 Loss CLCA4 Malignant mesothelioma
9 35962 1 69700000 116100000 Loss COL11A1 Malignant mesothelioma
10 35964 1 69700000 116100000 Loss TGFBR3 Malignant mesothelioma
11 35966 1 69700000 120600000 Loss Malignant mesothelioma
12 37056 1 84900000 107200000 Loss Malignant mesothelioma
13 69952 12 56600000 58100000 Gain Malignant mesothelioma
14 75172 13 17900000 45800000 Loss BRCA2 Malignant mesothelioma
15 85738 14 50900000 107349540 Loss CCNK Malignant mesothelioma
16 85740 14 50900000 107349540 Loss CDKN3 Malignant mesothelioma
17 113645 17 44900000 81195210 Gain ERN1 Malignant mesothelioma
18 113647 17 44900000 81195210 Gain MAP3K3 Malignant mesothelioma
19 113649 17 44900000 81195210 Gain PRKCA Malignant mesothelioma
20 113651 17 44900000 81195210 Gain SMARCD2 Malignant mesothelioma
21 175422 3 39400000 63700000 Loss CACNA2D3 Malignant mesothelioma
22 175424 3 39400000 63700000 Loss CTNNB1 Malignant mesothelioma
23 175426 3 39400000 63700000 Loss MLH1 Malignant mesothelioma
24 175771 3 44100000 44200000 Loss Malignant mesothelioma
25 187512 4 50400000 191154276 Loss Malignant mesothelioma
26 191705 5 1 48400000 Gain Malignant mesothelioma
27 204729 6 114600000 118300000 Loss HDAC2 Malignant mesothelioma
28 204731 6 114600000 118300000 Loss MARCKS Malignant mesothelioma
29 217075 7 1 4500000 Gain Malignant mesothelioma
30 234871 8 139900000 146364022 Gain Malignant mesothelioma
31 250026 9 19900000 25600000 Loss C9orf14 Malignant mesothelioma
32 250029 9 19900000 25600000 Loss CDKN2A Malignant mesothelioma
33 250031 9 19900000 25600000 Loss CDKN2B Malignant mesothelioma
34 250069 9 19900000 33200000 Loss Malignant mesothelioma
35 251883 9 33200000 36300000 Gain Malignant mesothelioma

Expression for Mesothelioma, Malignant

Search GEO for disease gene expression data for Mesothelioma, Malignant.

Pathways for Mesothelioma, Malignant

Pathways related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.84 BAP1 KRT7 MUC1 NF2 VIM
2 11.5 CDKN2A MIR203A MIR345 MIR423 VIM
3 11.2 CDH2 VIM WT1
4 10.51 CDH2 VIM

GO Terms for Mesothelioma, Malignant

Cellular components related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.02 MIR203A MIR345 MIR423 MIR582 MIR584

Biological processes related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.35 BCL10 CDKN2A NKX2-1 SPP1 WT1
2 gene silencing by miRNA GO:0035195 9.02 MIR203A MIR345 MIR423 MIR582 MIR584

Molecular functions related to Mesothelioma, Malignant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR203A MIR345 MIR423 MIR582

Sources for Mesothelioma, Malignant

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....